In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novo Nordisk: Riding High on Diabetes

Executive Summary

Novo Nordisk is confident that it can continue to generate strong growth from its leading diabetes franchise. Having exited oral anti-diabetics, it's betting on further innovation in insulin and on a strong entry into the GLP-1 analog space.
Advertisement

Related Content

Personalizing Patient Care:Sanofi Recasts Its Diabetes Efforts
Enject's GlucaPen: Mightier than the Hypo-kit?
Regulatory Risk and Business Development: Type 2 Diabetes Falls Out of Favor
Inhaled Insulin is Dead. Long Live Inhaled Insulin
Taking Aim at Diabetes
Novo-ZymoGenetics: The Next Roche-Genentech?
Amgen's Biotech Shopping Spree
Can Amgen Find a New Engine?
Can Amgen Find a New Engine?
Tercica Gives Ipsen US Foothold

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV002960

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel